Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Current Drug Targets|March 5, 2015
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)Joshua F Zeidner, Matthew C Foster
Statistics in Medicine|February 3, 2016
The rapid enrollment design for Phase I clinical trialsAnastasia Ivanova, Yunfei Wang, Matthew C Foster
Journal of Biopharmaceutical Statistics|June 29, 2019
Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groupsXiaoqiang Xue, Matthew C Foster, Anastasia Ivanova
Peerj|February 6, 2015
Effects of five southern California macroalgal diets on consumption, growth, and gonad weight, in the purple sea urchin Strongylocentrotus purpuratusMatthew C Foster, Jarrett E K Byrnes, Daniel C Reed
Current Hematologic Malignancy Reports|February 20, 2021
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment OptionsDaniel R Richardson, Steven D Green, Matthew C Foster, et al.
Seminars in Oncology Nursing|November 25, 2019
Advances in Genomic Profiling and Risk Stratification in Acute Myeloid LeukemiaDaniel R Richardson, Matthew C Foster, Catherine C Coombs, et al.
Archives of Pathology & Laboratory Medicine|February 2, 2013
Diagnostic complexities of eosinophiliaNathan D Montgomery, Cherie H Dunphy, Micah Mooberry, et al.
Oncology Nursing Forum|June 24, 2026
Caregivers' Perspectives on Cancer-Related Cognitive Impairment in Older Adults With Acute Myeloid Leukemia Receiving ChemotherapyYa-Ning Chan, Youngmin Cho, Rachel Hirschey, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 3, 2024
Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descriptive studyYa-Ning Chan, Youngmin Cho, Rachel Hirschey, et al.
Journal of the National Cancer Institute|November 11, 2015
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer InstituteJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Pageof 4